PUMA BIOTECHNOLOGY Clinical Trials

Company details

Status: Public
HQ: 10880 Wilshire Blvd, Los Angeles, CA 90024, US
Founded: 2010
Employees: 257
Programs: 40
Drugs: 23
Patents: 1

Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

Puma Biotechnology Inducement Awards: Strategic Talent Moves Under Nasdaq Rule 5635(c)(4) Jun 7, 2026

View all news & analysis →

Recent trial activity

8 updates

Latest clinical program signals indexed for PUMA BIOTECHNOLOGY.

Trial registry

58 studies

2024-511497-79-00
PUMA-ALI-1201

Phase 2 active small_molecule

Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)

CTIS ↗
NCT00146172
neratinib

Phase 2 completed small_molecule

Breast Neoplasms

CT.gov ↗
NCT00266877
HKI-272

Phase 2 completed small_molecule

Carcinoma, Non-Small-Cell Lung

CT.gov ↗
NCT00300781
neratinib

Phase 2 completed small_molecule

Breast Neoplasms

CT.gov ↗
NCT00366600
neratinib

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT00380328
neratinib

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT00397046
neratinib

Phase 1 completed small_molecule

Tumors

CT.gov ↗
NCT00398567
HKI-272

Phase 2 completed small_molecule

Advanced Breast Cancer

CT.gov ↗
NCT00445458
HKI-272

Phase 2 completed small_molecule

Advanced Breast Cancer

CT.gov ↗
NCT00498745
neratinib

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT00550212
neratinib

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT00706030
Neratinib

Phase 2 completed small_molecule

Breast Cancer

CT.gov ↗
NCT00708903
Neratinib

Phase 2 completed small_molecule

Breast Cancer

CT.gov ↗
NCT00741260
Neratinib

Phase 2 completed small_molecule

Breast Cancer

CT.gov ↗
NCT00757809
Neratinib

Phase 1 completed small_molecule

Healthy Subjects

CT.gov ↗
NCT00768469
Neratinib

Phase 1 completed small_molecule

Advanced Malignant Solid Tumors

CT.gov ↗
NCT00777101
Neratinib

Phase 2 completed small_molecule

Advanced Breast Cancer

CT.gov ↗
NCT00781430
Neratinib (HKI-272)

Phase 1 completed small_molecule

Hepatic Insufficiency

CT.gov ↗
NCT00814060
Neratinib

Phase 1 completed small_molecule

Healthy Subjects

CT.gov ↗
NCT00838539
Neratinib

Phase 1 completed small_molecule

Neoplasms

CT.gov ↗
NCT00860223
Digoxin

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT00864487
Neratinib

Phase 1 completed small_molecule

Healthy Subjects

CT.gov ↗
NCT00878709
Neratinib

Phase 2 completed small_molecule

Breast Cancer

CT.gov ↗
NCT00915018
Neratinib

Phase 2 completed small_molecule

Breast Cancer

CT.gov ↗
NCT00932464
neratinib

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT00958724
Neratinib

Phase 1 completed small_molecule

Advanced Malignant Solid Tumors

CT.gov ↗
NCT01008150
Paclitaxel

Phase 2 completed small_molecule

Breast Cancer

CT.gov ↗
NCT01111825
Temsirolimus

Phase 2 completed small_molecule

Breast Cancer

CT.gov ↗
NCT01128842
Neratinib

Phase 1 completed small_molecule

Advanced Malignant Solid Tumors

CT.gov ↗
NCT01494662
HKI-272

Phase 2 completed small_molecule

Breast Cancer

CT.gov ↗
NCT01670877
neratinib

Phase 2 completed small_molecule

Breast Neoplasms

CT.gov ↗
NCT01808573
neratinib

Phase 3 completed small_molecule

HER2+ Metastatic Breast Cancer (MBC)

CT.gov ↗
NCT01827267
neratinib

Phase 2 completed small_molecule

HER2-mutant Non-Small Cell Lung Cancer

CT.gov ↗
NCT01953926
Neratinib

Phase 2 terminated small_molecule

Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

CT.gov ↗
NCT02236000
Neratinib

Phase 2 completed small_molecule

Breast Cancer

CT.gov ↗
NCT02334501
Lansoprazole

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT02400476
Neratinib

Phase 2 completed small_molecule

Early Stage HER2+ Breast Cancer

CT.gov ↗
NCT02977780
Temozolomide

Phase 2 active small_molecule

Glioblastoma

CT.gov ↗
NCT03094052
Neratinib

Phase 2 completed small_molecule

HER2-positive Breast Cancer

CT.gov ↗
NCT03289039
Neratinib

Phase 2 completed small_molecule

Breast Cancer

CT.gov ↗
NCT03377387
Capecitabine

Phase 2 active small_molecule

Breast Cancer

CT.gov ↗
NCT03457896
Trastuzumab

Phase 2 active small_molecule

Metastatic Colorectal Cancer

CT.gov ↗
NCT03812393
Neratinib

Phase 2 active small_molecule

Triple Negative Breast Cancer

CT.gov ↗
NCT03919292
Neratinib

Phase 2 active small_molecule

Solid Tumor, Adult

CT.gov ↗
NCT04085315
Osimertinib

Phase 1 active small_molecule

Lung Cancer Metastatic

CT.gov ↗
NCT04366713
Neratinib

Phase 2 completed small_molecule

HER2 Amplified Breast Cancer

CT.gov ↗
NCT04502602
Neratinib 160 mg

Phase 1 active small_molecule

Advanced Solid Tumor

CT.gov ↗
NCT04781374
Neratinib

Phase 2 terminated small_molecule

Metastatic Prostate Adenocarcinoma

CT.gov ↗
NCT04886531
Neratinib

Phase 2 completed small_molecule

Breast Cancer

CT.gov ↗
NCT04901299
NERATINIB

Phase 2 terminated small_molecule

Stage IV (Metastatic) Breast Cancer

CT.gov ↗
NCT05243641
Neratinib

Phase 2 terminated small_molecule

Metastatic Breast Cancer

CT.gov ↗
NCT05252988
Neratinib

Phase 2 active small_molecule

Early-stage Breast Cancer

CT.gov ↗
NCT05274048
Neratinib Pill

Phase 1 active small_molecule

Gastric Cancer

CT.gov ↗
NCT05919108
Neratinib

Phase 2 active small_molecule

Anatomic Stage I Breast Cancer

CT.gov ↗
NCT06095505
Alisertib

Phase 2 active small_molecule

Small Cell Lung Cancer

CT.gov ↗
NCT06109467
Neratinib

Phase 2 active small_molecule

GastroEsophageal Cancer

CT.gov ↗
NCT06369285
Alisertib

Phase 2 active small_molecule

Hormone Receptor Positive HER-2 Negative Breast Cancer

CT.gov ↗
NCT07465757
Alisertib

Phase 2 active small_molecule

Small Cell Lung Cancer ( SCLC )

CT.gov ↗

Recent trial activity

Trial registry

Stay Ahead in Pharma